Menu
Search
|

Menu

Close
X

Theravance Biopharma Inc TBPH.OQ (NASDAQ Stock Exchange Global Market)

27.95 USD
+0.91 (+3.37%)
As of Feb 23
chart
Previous Close 27.04
Open 27.10
Volume 69,582
3m Avg Volume 68,203
Today’s High 28.00
Today’s Low 26.50
52 Week High 43.30
52 Week Low 22.94
Shares Outstanding (mil) 54.10
Market Capitalization (mil) 1,512.19
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.86 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY17
11
FY16
49
FY15
42
EPS (USD)
FY17
-3.805
FY16
-4.251
FY15
-5.324
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.62
Price to Sales (TTM)
vs sector
91.30
8.35
Price to Book (MRQ)
vs sector
8.21
5.22
Price to Cash Flow (TTM)
vs sector
--
25.88
Total Debt to Equity (MRQ)
vs sector
121.38
15.84
LT Debt to Equity (MRQ)
vs sector
121.38
12.39
Return on Investment (TTM)
vs sector
-71.05
13.63
Return on Equity (TTM)
vs sector
-110.30
15.39

EXECUTIVE LEADERSHIP

Rick Winningham
Chairman of the Board, Chief Executive Officer, Since
Salary: $903,545.00
Bonus: $189,744.00
Renee Gala
Senior Vice President, Chief Financial Officer, Treasurer, Since 2014
Salary: $429,525.00
Bonus: $75,167.00
Bradford Shafer
Executive Vice President, General Counsel, Secretary, Since 2016
Salary: $478,413.00
Bonus: $87,510.00
Brett Haumann
Senior Vice President - Clinical Development and Chief Medical Officer, Since 2016
Salary: --
Bonus: --
Sharathchandra Hegde
Senior Vice President, Research, Since 2014
Salary: $392,515.00
Bonus: $62,994.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

UGLAND HOUSE, SOUTH CHURCH STREE
GEORGE TOWN     KY1-1104

Phone:

Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.

SPONSORED STORIES